Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
LITESPARK-003 trial: what clinicians have said so far
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
- NCT03634540 ↗
- Active, not recruiting
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on LITESPARK-003 (belzutifan plus cabozantinib in advanced clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LITESPARK-003 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 8 posts on X, typically up to 35 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney
- Interventions
- Belzutifan; Cabozantinib
- Arms
- Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1) · Experimental
- Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2) · Experimental
- Enrollment
- 118 (estimated)
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Start
- Sep 27, 2018
- Primary completion
- Feb 26, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03634540 · updated Dec 20, 2024
Publications
linked from the registry- Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D'Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31. PubMed 37011650
- Choueiri TK, Merchan JR, Figlin R, McDermott DF, Arrowsmith E, Michaelson MD, Tykodi SS, Heath EI, Spigel DR, D'Souza A, Kassalow L, Perini RF, Vickery D, Bauer TM. Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study. Lancet Oncol. 2025 Jan;26(1):64-73. doi: 10.1016/S1470-2045(24)00649-1. PubMed 39756444